References

  1. American Cancer Society. Breast cancer facts and figures 2010. Atlanta American Cancer Society.2010.

  2. Lansac J, Lecomte P et Marret H. Gynécologie pour le praticien. 8e édition, Elsevier Masson, Paris, 2012.r

  3. Mignotte H. maladies du sein. 2e édition. Elsevier Masson, 2011.

  4. Dignostic and therapeutical management of malignant pleural effusion, Tassi, Ann. Onc 2006 Mar, 17. Google Scholar

  5. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 May 16;351(9114):1451-67. PubMed | Google Scholar

  6. Brauner M, Brillet PY. Other malignant tumors of the pleura. Rev Pneumol Clin. 2006 Apr;62(2):124-7. PubMed | Google Scholar

  7. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst. 2001 Jan 17;93(2):96-111. PubMed | Google Scholar

  8. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphoedema. Cancer. 1998; 83(12 Suppl): 2776-81. PubMed | Google Scholar

  9. Arrault M et Vigne S. facteurs de risques de développement d?un lympoedeme du membre supérieur après traitement du cancer du sein. Bull Cancer. 2006 ; 93 (10) : 1001-6. PubMed | Google Scholar

  10. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survi- val : an overview of the randomised trials. Lancet. 2005 ; 365 (9472) : 1687-17717. Google Scholar

  11. Baum M, Hackshaw A, Houghton J et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006 ; 42 (7) : 895-904. PubMed | Google Scholar

  12. Fisher B, Dignam J, Bryant J, Wolmark N.. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001 May 2;93(9):684-90. Google Scholar

  13. Sacco M, Valentini M, Belfiglio M, Pellegrini F, De Berardis G, et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol. 2003 Jun 15;21(12):2276-81. Google Scholar